|
US5651970A
(en)
*
|
1993-03-19 |
1997-07-29 |
Allen; Allen D. |
Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics
|
|
DE4435950A1
(de)
*
|
1994-10-07 |
1996-04-11 |
Hoechst Ag |
Copolymerisate mit cyclischen oder polycyclischen Monomeren mit einer speziellen Isomerenverteilung und deren Einsatz in Beschichtungsmitteln
|
|
US5961976A
(en)
*
|
1996-06-03 |
1999-10-05 |
United Biomedical, Inc. |
Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
|
|
AU3044697A
(en)
*
|
1997-06-24 |
1999-01-04 |
Norman Godin |
A composition for specific immunoprotection and method for obtaining said comp osition
|
|
US6420545B1
(en)
*
|
1999-05-24 |
2002-07-16 |
The Trustees Of The University Of Pennsylvania |
CD4-independent HIV envelope proteins as vaccines and therapeutics
|
|
CA2382161A1
(en)
*
|
1999-09-03 |
2001-03-15 |
Human Genome Sciences, Inc. |
Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
|
|
WO2001043779A2
(en)
*
|
1999-12-16 |
2001-06-21 |
Tanox, Inc. |
Anti-hiv-1 conjugates for treatment of hiv disease
|
|
AU2003299085B2
(en)
*
|
2002-09-27 |
2008-04-10 |
Tanox, Inc. |
Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
|
|
EP1460088A1
(en)
*
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
WO2007094983A2
(en)
*
|
2006-02-03 |
2007-08-23 |
Tanox, Inc. |
Methods and compositions for the inhibition of hiv infection of t cells
|
|
TW200817438A
(en)
|
2006-08-17 |
2008-04-16 |
Hoffmann La Roche |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
|
WO2008019817A1
(en)
*
|
2006-08-17 |
2008-02-21 |
F. Hoffmann-La Roche Ag |
A conjugate of an antibody against ccr5 and an antifusogenic peptide
|
|
TW200902544A
(en)
*
|
2007-03-13 |
2009-01-16 |
Hoffmann La Roche |
Peptide-complement conjugates
|
|
US20130195881A1
(en)
|
2007-04-27 |
2013-08-01 |
Sanjaya Singh |
Potent, stable and non-immunosuppressive anti-cd4 antibodies
|
|
US20090022720A1
(en)
|
2007-07-20 |
2009-01-22 |
Stephan Fischer |
Conjugate of an antibody against CD4 and antifusogenic peptides
|
|
SG190598A1
(en)
*
|
2008-03-13 |
2013-06-28 |
Biotest Ag |
Agent for treating disease
|
|
KR20100135808A
(ko)
*
|
2008-03-13 |
2010-12-27 |
바이오테스트 아게 |
질병 치료제
|
|
EP2262838B1
(en)
*
|
2008-03-13 |
2016-04-13 |
Biotest AG |
Agent for treating disease
|
|
MX2011001583A
(es)
|
2008-08-11 |
2011-04-04 |
Nektar Therapeutics |
Conjugados de alcanoato polimericos de multiples brazos.
|
|
DK2341937T3
(en)
*
|
2008-09-29 |
2015-02-09 |
Biotest Ag |
Composition for the treatment of a disease
|
|
EP2246364A1
(en)
*
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Anti CXCR4 antibodies for the treatment of HIV
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
|
WO2012088445A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
|
WO2012166555A1
(en)
|
2011-05-27 |
2012-12-06 |
Nektar Therapeutics |
Water - soluble polymer - linked binding moiety and drug compounds
|
|
RS57397B8
(sr)
|
2011-06-10 |
2020-01-31 |
Univ Oregon Health & Science |
Cmv glikoproteini i rekombinantni vektori
|
|
CN102321653B
(zh)
*
|
2011-07-18 |
2013-11-20 |
清华大学 |
人鼠嵌合型cd4质粒及其多抗在抑制hiv感染中的应用
|
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
|
JP6408487B2
(ja)
|
2012-12-18 |
2018-10-24 |
ザ ロックフェラー ユニバーシティ |
Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体
|
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3194442A4
(en)
|
2014-09-16 |
2018-05-23 |
UBI IP Holdings |
Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US10858760B2
(en)
|
2015-06-01 |
2020-12-08 |
Medigene Immunotherapies Gmbh |
T cell receptor library
|
|
JP2018517711A
(ja)
*
|
2015-06-01 |
2018-07-05 |
メディジーン イミュノテラピーズ ゲーエムベーハー |
細胞表面タンパク質に対する抗体を作製する方法
|
|
US9925258B2
(en)
|
2015-10-02 |
2018-03-27 |
International Aids Vaccine Initiative |
Replication-competent VSV-HIV Env vaccines
|
|
BR112018012826A2
(pt)
|
2015-12-23 |
2018-12-04 |
Medigene Immunotherapies Gmbh |
método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
|
|
KR20190071677A
(ko)
|
2016-08-13 |
2019-06-24 |
유나이티드 바이오파마, 인크. |
Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화
|
|
CN112175087B
(zh)
*
|
2019-07-02 |
2022-05-13 |
深圳市迈加瑞生物技术有限公司 |
一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
|
|
WO2021034913A1
(en)
*
|
2019-08-19 |
2021-02-25 |
The Rockefeller University |
Engineering ph-dependent antigen binding activity into anti-hiv antibodies with improved pharmacokinetics
|
|
WO2021062546A1
(en)
*
|
2019-10-01 |
2021-04-08 |
Taimed Biologics Inc. |
Use of ibalizumab for the treatment of hiv-2 infection
|
|
CN112500491B
(zh)
|
2020-12-18 |
2022-04-08 |
深圳市迈加瑞生物技术有限公司 |
一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
|
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向ｃｄ４之病毒載體之用途
|
|
US20250059560A1
(en)
|
2021-12-16 |
2025-02-20 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
EP4622631A1
(en)
|
2022-11-23 |
2025-10-01 |
University of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024220597A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Digital droplet based assay for detecting replication competent lentiviral vector
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
CN117659192A
(zh)
*
|
2023-10-19 |
2024-03-08 |
深圳市福元生物科技有限公司 |
Cd4纳米抗体的制备及其应用
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|